Gossamer Bio (GOSS) News Today $1.40 -0.13 (-8.50%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.71%) As of 02/21/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Gossamer Bio regains Nasdaq compliance with bid priceFebruary 22 at 12:02 AM | investing.comGossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILDFebruary 13, 2025 | seekingalpha.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | businesswire.comGossamer Bio showcases seralutinib studies at PVRI CongressFebruary 4, 2025 | msn.comGossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressFebruary 3, 2025 | businesswire.comHC Wainwright Weighs in on Gossamer Bio FY2029 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Gossamer Bio in a research note issued on Thursday, January 30th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $0.59 forJanuary 31, 2025 | marketbeat.comGossamer Bio’s Seralutinib Advances Propel Buy Rating Amid Strategic Developments and Expansion OpportunitiesJanuary 31, 2025 | markets.businessinsider.comGossamer Bio And 2 Other Promising Penny Stocks On US ExchangesJanuary 30, 2025 | finance.yahoo.comGossamer Bio's (GOSS) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Thursday.January 30, 2025 | marketbeat.comGossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual CongressJanuary 28, 2025 | finance.yahoo.comGossamer Bio’s Strategic Focus on PAH Unmet Needs and Seralutinib Efficacy Drives Buy RatingJanuary 27, 2025 | markets.businessinsider.comCantor Fitzgerald Predicts Gossamer Bio FY2025 EarningsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Gossamer Bio in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings per shareJanuary 22, 2025 | marketbeat.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 12.8% in DecemberGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 6,120,000 shares, a decrease of 12.8% from the December 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the days-to-cover ratio is currently 4.6 days.January 19, 2025 | marketbeat.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 | businesswire.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Up 10.0% in DecemberGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 7,020,000 shares, a growth of 10.0% from the November 30th total of 6,380,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is presently 5.4 days.December 31, 2024 | marketbeat.comLeerink Partnrs Boosts Earnings Estimates for Gossamer BioGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Leerink Partnrs increased their FY2024 earnings per share estimates for Gossamer Bio in a research note issued on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.32) for thNovember 14, 2024 | marketbeat.comGossamer Bio’s Strategic Advancements and Financial Resilience Support Buy RatingNovember 13, 2024 | markets.businessinsider.comHC Wainwright Boosts Earnings Estimates for Gossamer BioGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Analysts at HC Wainwright boosted their FY2024 EPS estimates for Gossamer Bio in a research note issued to investors on Monday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.18) per share for the yeNovember 13, 2024 | marketbeat.comGossamer Bio (GOSS) Gets a Buy from OppenheimerNovember 13, 2024 | markets.businessinsider.comIndustry Analysts Just Made A Sizeable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Revenue ForecastsNovember 12, 2024 | finance.yahoo.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | businesswire.comGossamer Bio, Inc. (NASDAQ:GOSS) Just Reported And Analysts Have Been Lifting Their Price TargetsNovember 11, 2024 | finance.yahoo.comPromising Progress and Expansion Potential of Gossamer Bio’s Seralutinib Drive Buy RatingNovember 11, 2024 | markets.businessinsider.comGossamer Bio (NASDAQ:GOSS) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday.November 11, 2024 | marketbeat.comGossamer Bio Reports Revenue Growth Amid Strategic CollaborationsNovember 9, 2024 | markets.businessinsider.comGossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | finance.yahoo.comGossamer Bio, Inc. (NASDAQ:GOSS) Sees Large Decline in Short InterestGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) saw a large drop in short interest in October. As of October 15th, there was short interest totalling 6,950,000 shares, a drop of 10.3% from the September 30th total of 7,750,000 shares. Based on an average trading volume of 899,400 shares, the days-to-cover ratio is currently 7.7 days.October 30, 2024 | marketbeat.comGossamer Bio management to meet with OppenhiemerOctober 22, 2024 | markets.businessinsider.comMillennium Management LLC Sells 898,042 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)Millennium Management LLC trimmed its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 13.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,597,378 shares of the company's stock after selling 89October 12, 2024 | marketbeat.comGossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 7, 2024 | businesswire.comMarshall Wace LLP Purchases 2,103,766 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)Marshall Wace LLP grew its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 170.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,335,511 shares of the company's stock after purchasing an additionaOctober 4, 2024 | marketbeat.comGossamer Bio (NASDAQ:GOSS) Stock, Short Interest ReportOctober 3, 2024 | benzinga.comSeveral Insiders Invested In Gossamer Bio Flagging Positive NewsOctober 3, 2024 | finance.yahoo.comGossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Down 5.8% in SeptemberGossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 8,550,000 shares, a decrease of 5.8% from the August 31st total of 9,080,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is presently 5.6 days.September 30, 2024 | marketbeat.comNEA Management Company LLC Buys 2,255,025 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)NEA Management Company LLC boosted its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 14.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,093,034 shares of the company'sSeptember 25, 2024 | marketbeat.comPresenting on the Emerging Growth Conference 75 Day 1 on September 25 Register NowSeptember 24, 2024 | finance.yahoo.comBullish Outlook on Gossamer Bio’s Seralutinib Efficacy and Market PotentialSeptember 18, 2024 | markets.businessinsider.comGossamer Bio (NASDAQ:GOSS) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday.September 17, 2024 | marketbeat.comGossamer Bio (GOSS) Receives a Buy from OppenheimerSeptember 16, 2024 | markets.businessinsider.com3 Penny Stocks To Buy With Just $50September 15, 2024 | 247wallst.comAcadian Asset Management LLC Has $3.24 Million Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)Acadian Asset Management LLC boosted its position in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 31.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,592,765 shares of the company's stock afteSeptember 13, 2024 | marketbeat.comMonaco Asset Management SAM Raises Stock Position in Gossamer Bio, Inc. (NASDAQ:GOSS)Monaco Asset Management SAM boosted its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 390.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,726,104 shares of the company's stock after acquSeptember 10, 2024 | marketbeat.comGossamer Bio Has One More Shot On Goal And Is Not Likely To MissSeptember 10, 2024 | seekingalpha.comResearch Analysts Issue Forecasts for Gossamer Bio, Inc.'s Q3 2024 Earnings (NASDAQ:GOSS)Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for Gossamer Bio in a research report issued on Thursday, August 29th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earSeptember 2, 2024 | marketbeat.comGossamer Bio's (GOSS) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Friday.August 30, 2024 | marketbeat.comGossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024August 27, 2024 | stockhouse.comAnalysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) ForecastsAugust 21, 2024 | finance.yahoo.comWhat It Takes to Perform Brain SurgeryAugust 16, 2024 | msn.comWith 73% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big gunsAugust 16, 2024 | finance.yahoo.comQ3 2024 Earnings Forecast for Gossamer Bio, Inc. (NASDAQ:GOSS) Issued By Leerink PartnrsGossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at Leerink Partnrs raised their Q3 2024 EPS estimates for Gossamer Bio in a research note issued on Tuesday, August 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.21) per sharAugust 15, 2024 | marketbeat.com Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Media Mentions By Week GOSS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GOSS News Sentiment▼0.000.60▲Average Medical News Sentiment GOSS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GOSS Articles This Week▼12▲GOSS Articles Average Week Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SYRE News Today SPRY News Today OCUL News Today XNCR News Today ETNB News Today GYRE News Today AUPH News Today NTLA News Today MRVI News Today ELVN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GOSS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
